αvβ3 Integrin Antagonists Enhance Chemotherapy Response in an Orthotopic Pancreatic Cancer Model

Pancreatic cancer decreases survival time and quality of life because of drug resistance and peripheral neuropathy during conventional treatment. This study was undertaken to investigate whether αvβ3 integrin receptor antagonist compounds NDAT and XT199 can suppress the development of cisplatin resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Debreli Coskun, Melis, Sudha, Thangirala, Bharali, Dhruba J., Celikler, Serap, Davis, Paul J., Mousa, Shaker A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7056702/
https://www.ncbi.nlm.nih.gov/pubmed/32174830
http://dx.doi.org/10.3389/fphar.2020.00095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7056702/
https://www.ncbi.nlm.nih.gov/pubmed/32174830
http://dx.doi.org/10.3389/fphar.2020.00095

Ejemplares similares